Patients treated with either mitoxantrone or interferon who experienced adverse events
| Mitoxantrone | Interferon | p Value | |
| N=55 | N=54 | ||
| Upper-respiratory-tract infection | 25 | 13 | 0.019 |
| Leucopenia | 20 | 9 | 0.020 |
| Nausea | 12 | 4 | 0.034 |
| Persistent amenorrhoea* | 2/36 | 0/36 | 0.493 |
| Light alopecia | 5 | 1 | 0.206 |
| Transient left ventricular ejection fraction* <50% | 2 | 0 | 0.495 |
| Neutropenia* <500 and fever | 2 | 0 | 0.495 |
↵* Even if the observed differences are not statistically different, the occurrence of these events was expected in the mitoxantrone group, and the treating neurologist should be aware of these.